Viking therapeutics drops 40% on medicinal dates
Shares of Viking therapeutics On Tuesday, the company dived with medium test data for its obesity pill, which disappointed the investors.
The share price of the BioTech company fell to around $ 23.80 from Tuesday morning, from $ 42.09 until the end of Monday, a jump of around 43%. Viking's market capitalization is now around 2.69 billion US dollars, compared to more than 4 billion US dollars on Monday.
The results could be a blow for Viking, which was once seen as a hot M&A goal as a pharmaceutical company to turn to the booming market for obesity and diabetes. It could reinforce Eli Lilly And Novo NordiskThe dominance in the room, especially if you develop pills for weight loss, could occur years before the tablet formulation of the VK2735 -VK2735 from Viking.
Jared Holz, Mazuho Health Care Equity Strategist, said on Tuesday in an e -mail that the data “probably hope for shutters [Viking] To be a big player on the oral obesity market everywhere until medium term. “
The race for a more comfortable pill of obesity was corrected like companies and companies Pfizer had to scrap earlier competitors and produce new ones.
Viking's once daily pill helped the patient to lose up to 12.2% of their weight at about three months. The company also said that weight loss is not a plateau, which means that patients could lose even more in a longer -term study.
It is difficult to compare the PILL phase -zi -Zwei -Zwei -Data directly with the results of the oral medicines in development, including the treatments developed by Eli Lilly and Novo Nordisk.
Wood added that the results of Viking's pill “inferior” for those of Eli Lilly's oral drugs on almost all metrics “. The highest dose of eli lillys daily daily pill helped the patient, 12.4% of their body weight or 11.2% regardless of the interruption after 72 weeks in a phase thirty study.
Wood pointed out the high rate of patients who set the drug from Viking for more than 13 weeks, which was around 28%. In the meantime, about a quarter of the people of Eli Lillys Pille, Oforlipron, hired over 72 weeks for some reason.
This is “a much longer exam and therefore [Lilly] Looks much better, “said Holz.
Viking said that the most common reasons for patients to cancel treatment were gastrointestinal side effects, most of which were difficult to moderate severity and were previously observed during treatment. However, around 58% of the patients with the pill stated that they had nausea, and 26% experienced vomiting compared to 48% or 10%, for which a placebo took.
These side effect rates over a shorter test period seem to be worse than those in experiments to Eli Lilly's pill and the oral version of Nordis's weight loss drug Wegovy.
The treatment of Viking works by imitation of two naturally produced intestinal hormones, which are referred to as GLP-1 and GIP.
GLP-1 helps to reduce food intake and appetite. Gip, which also suppresses appetite, can also improve the way the body breaks sugar and fat.
Eli Lillys Pille and the oral version of Nordo Nordisks Wegovy both aimed at GLP-1, but the latter has dietary restrictions.
